Escherichia coli Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Escherichia coli Infections – Drugs In Development, 2023’, provides an overview of the Escherichia coli Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections
- The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects
- The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
ABAC Therapeutics SAAbera Bioscience AB
Affilogic SAS
Alterity Therapeutics Ltd
Arizona State University
Armata Pharmaceuticals Inc
AstraZeneca Plc
Atterx Biotherapeutics Inc
BB100 LLC
Biomendics LLC
ContraFect Corp
Dong-A ST Co Ltd
Eligo Bioscience SA
Entasis Therapeutics Holdings Inc
EveliQure Biotechnologies GmbH
F. Hoffmann-La Roche Ltd
Florida International University
Forge Therapeutics Inc
GlyProVac ApS
Immunethep SA
Immuron Ltd
Institute for Development Research
iNtRON Biotechnology Inc
Johns Hopkins University
Johnson & Johnson
Lehigh University
Linnaeus Bioscience Inc
Massachusetts Institute of Technology
Meiji Seika Pharma Co Ltd
Melinta Therapeutics LLC
Merck & Co Inc
MetalloBio Ltd
Microbiotix Inc
Nanyang Technological University
Nektr Technologies Ltd
Neoculi Pty Ltd
Northeastern University
Northern Antibiotics Oy
Nosopharm SAS
NYU Langone Health System
Ostrich Pharma USA Inc
Oxford Drug Design Ltd
Pedanius Therapeutics Ltd
Peptilogics Inc
PGTx Ltd
Phico Therapeutics Ltd
Planet Biotechnology Inc
Protein Potential LLC
Pylum Biosciences Inc
Recce Pharmaceuticals Ltd
RemAb Therapeutics SL
Shanghai Space Peptides Pharmaceutical Co Ltd
SNIPR Biome ApS
Spero Therapeutics Inc
Spexis AG
Swansea University
Syntiron LLC
Telum Therapeutics SL
The University of Texas at Austin
University College Dublin
University of Auckland
University of California Los Angeles
University of Iowa
University of Lucknow
University of Michigan
University of Oklahoma
University of Strathclyde
University Pompeu Fabra
VenatoRx Pharmaceuticals Inc
Venus Medicine Research Centre